Marta Weinstock-Rosin
Director/Board Member at Avraham Pharmaceuticals Ltd.
Profile
Marta Weinstock-Rosin is the founder of Spero Biopharma Ltd.
She is currently a Director at Avraham Pharmaceuticals Ltd.
and a Professor-Emeritus at The Hebrew University of Jerusalem.
Previously, she served as the President of The Israel Society for Neuroscience from 2005 to 2005.
Marta Weinstock-Rosin active positions
Companies | Position | Start |
---|---|---|
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Director/Board Member | - |
The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Former positions of Marta Weinstock-Rosin
Companies | Position | End |
---|---|---|
The Israel Society for Neuroscience | President | 2004-12-31 |
Spero Biopharma Ltd.
Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Founder | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
The Israel Society for Neuroscience | |
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
Spero Biopharma Ltd.
Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Health Technology |
- Stock Market
- Insiders
- Marta Weinstock-Rosin